United States

AFFO (TTM)

AFFO/share (TTM)

AFFO/share Guidance

AFFO (Quarter)

AFFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/AFFO

Size (ft²)

Occupancy

The Company is a fully integrated REIT primarily focused on the ownership, acquisition, development and management of
retail properties net leased to industry leading tenants.

Agree Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, ADC is classified as investment grade

Period: 2023 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2026 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 10/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2026 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Adjusted FFO

Adjusted FFO Growth

Assessment of recent increases in Adjusted FFO per share, indicating profitability

Adjusted FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Retirees heading into fall want two things from an income portfolio: a check that shows up every 30 days, and a dividend that will not be cut.

5 Safest High-Yield Monthly Pay Dividend Stocks Retirees Trust in August

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company's potential first-in-class Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), for the treatment of neuroendocrine carcinomas (NECs). NECs are aggressive malignancies that frequently express DLL3. There are no available targeted therapies.

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in process SINGAPORE and NORTH BRUNSWICK, N.J.

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

Agree Realty NYSE: ADC reported record second-quarter investment activity and raised its full-year outlook, citing strong acquisition, development and portfolio performance.

Agree Realty Q2 Earnings Call Highlights

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended June 30, 2026. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Second Quarter 2026 Financial and Operating Highlights: Invested a Company record of approximately $502 million in 102 retail net lease properties Commenced five development or Developer Funding Platform (“DFP”) projects for total committed capita.

Agree Realty Corporation Reports Second Quarter 2026 Results

Enrollment progressing in ASCEND Phase 1/2 global clinical trial evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients CR-001 + sacituzumab tirumotecan (sac-TMT) Phase 2 trial in NSCLC, first ADC combination study in Kelun-Biotech collaboration, underway in China Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China; Phase 1/2 global trial of CR-002, a PD-L1-targeted ADC, on track to initiate in second half of 2026 Multiple key clinical data readouts across the portfolio anticipated beginning in Q1 2027 Completed $143.7 million public offering extending expected cash runway into the second half of 2028 WALTHAM, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the second quarter ended June 30, 2026 and recent business highlights.

Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

For retirees who prefer their paychecks to arrive every 30 days instead of every 90, a small corner of the market delivers just that.

5 Boomer-Proof Monthly Dividend Stocks That Pay You While You Sleep

Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) demonstrated a statistically significan

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Realty Income (NYSE:O | O Price Prediction) gets most of the airtime in retiree circles, but it is not the only quality REIT engineered to write dividend checks year after year.

Forget Realty Income: 4 Other REITs Built for Dividend Investors

California Public Employees Retirement System lessened its position in shares of Agree Realty Corporation (NYSE: ADC) by 7.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 276,624 shares of the real estate investment trust's stock after selling 23,684

Agree Realty Corporation $ADC Stock Holdings Trimmed by California Public Employees Retirement System

Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform

Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced the completion of enrollment in the dose e

Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)

ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation

Few things ruin a Saturday morning faster than the words "your timing chain is going." Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as property taxes or insurance renewals. The fix is a small, dedicated slice of capital whose only job is to absorb those... The Portfolio That Pays All Your Car Repairs For Life

The Portfolio That Pays All Your Car Repairs For Life

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the third quarter of 2025. The dividend is payable August 14, 2026 to stockholders o.

Agree Realty Declares Monthly Common and Preferred Dividends

In the working world, paychecks show up every two weeks. Or at least, every month.

The 12.9% Monthly Dividend That Quietly Eats Your Portfolio

BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the clinical trial of novel CDH17 targeted ADC, ICP-B208, in China. Developed from InnoCare's in-house ADC platform, ICP-B208 is a novel ADC comprising a humanized anti-CDH17 monoclonal antibody conjugated to a potent, in-house invented payload via a protease-cleavable linker.

InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China

Income investors heading into July face a friendlier setup than they did just six weeks ago.

5 Safe Monthly Pay Dividend Stocks Boomers Love in July

LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on July 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.

ADC Therapeutics Announces New Employee Inducement Grant

Agree Realty Corporation (NYSE: ADC) (the âCompanyâ) today announced that it will release its second quarter 2026 operating results after the market closes

Agree Realty Announces Second Quarter 2026 Earnings Release Date and Conference Call Information

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its second quarter 2026 operating results after the market closes on Thursday, July 30, 2026. A conference call to discuss the Company's operating results is scheduled for Friday, July 31, 2026, at 10:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (833) 461-5787 International (626) 884-3620  .

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (r/r DLBCL). LOTIS-7 trial enrollment is now complete with 100 r/r DLBCL patients dosed at the selected 150 µg/kg dose of ZYNLONTA plus glofitamab.

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026 LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a strategic reorganization to focus resources behind key value-driving initiatives in support of the ZYNLONTA® (loncastuximab tesirine-lpyl) franchise. As part of the reorganization, ADC Therapeutics plans to reduce its workforce globally by approximately 17 percent.

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

AU, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)--Araris Biotech AG, a company advancing a differentiated pipeline of antibody-drug conjugates (“ADCs”) therapies, and Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, both members of the Taiho group, today announced that the first patient has been dosed in a Phase 1 clinical trial of ARC-02, a CD79b-targeted antibody-drug conjugate (ADC) for the treatment of non-Hodgk.

Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma

PARIS--(BUSINESS WIRE)-- #adc--One Biosciences receives Paris-Saclay Cancer Cluster (PSCC) BOOST grant to develop first single-cell assay for antibody-drug conjugates therapies.

One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies

NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

ZURICH, SWITZERLAND – June 18, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform and its potential to enable more precise and targeted cancer therapies. VERAXA will attend the BIO International Convention in San Diego, Calif.

VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.

10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA – ADCT

HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy or in combination with ivonescimab for the treatment of advanced breast cancer. HER3 is broadly expressed across various solid tumors, including breast, ovarian, colon, gastric, lung, skin, and pancreatic cancers, affecting millions of patients globally.

Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Opht

Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and P

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

Agree Realty (NYSE:ADC) and Global Net Lease (NYSE:GNL) own the same kind of asset — single-tenant properties leased on long-term, triple-net terms — and report it very differently.

Agree Realty And Global Net Lease: One Yields 4%, One Yields 8%. The Balance Sheet Sets The Spread.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has approved the Biologics License Appl

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the second quarter of 2025. The dividend is payable July 15, 2026 to stockholders of.

Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential

Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026

ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study testing its blood cancer drug showed more deaths among ​treated patients, despite meeting its main goal of improving progression-free survival.

ADC Therapeutics plunges after patient deaths in blood cancer drug trial

Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

SHANGHAI & CAMBRIDGE, MASS.--(BUSINESS WIRE)--ZAI LAB LIMITED (NASDAQ: ZLAB; HKEX: 9688) TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED ORPHAN DRUG DESIGNATION (ODD) TO ZOCILURTATUG PELITECAN (ZOCI, FORMERLY ZL-1310), THE COMPANY'S POTENTIAL FIRST-IN-CLASS DELTA-LIKE LIGAND 3 (DLL3) ANTIBODY-DRUG CONJUGATE (ADC), FOR THE TREATMENT OF NEUROENDOCRINE CARCINOMAS (NECS). NECS ARE AGGRESSIVE MALIGNANCIES THAT FREQUENTLY EXPRESS DLL3. THERE ARE NO AVAILABLE TARGETED THERAPIES.

U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO ZAI LAB'S DLL3-TARGETING ADC ZOCILURTATUG PELITECAN (ZOCI) FOR THE TREATMENT OF NEUROENDOCRINE CARCINOMAS (NECS)

FIRST-IN-CLASS PAN-RAS(ON) ADC IS CLEARED FOR CLINICAL DEVELOPMENT DESIGNED TO SELECTIVELY DELIVER PAN-RAS(ON) INHIBITION TO TUMORS WHILE MINIMIZING SYSTEMIC TOXICITY. IND SUBMISSIONS TO U.S. FDA AND CHINA NMPA ARE IN PROCESS SINGAPORE AND NORTH BRUNSWICK, N.J.

ADLAI NORTYE ANNOUNCES CLINICAL TRIAL NOTIFICATION SUBMISSION AND HREC APPROVAL FOR THE PHASE I CLINICAL TRIAL OF PAN-RAS(ON) INHIBITOR ADC AN4035 IN AUSTRALIA

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE QUARTER ENDED JUNE 30, 2026. ALL PER SHARE AMOUNTS INCLUDED HEREIN ARE ON A DILUTED PER COMMON SHARE BASIS UNLESS OTHERWISE STATED. SECOND QUARTER 2026 FINANCIAL AND OPERATING HIGHLIGHTS: INVESTED A COMPANY RECORD OF APPROXIMATELY $502 MILLION IN 102 RETAIL NET LEASE PROPERTIES COMMENCED FIVE DEVELOPMENT OR DEVELOPER FUNDING PLATFORM (DFP) PROJECTS FOR TOTAL COMMITTED CAPITA.

AGREE REALTY CORPORATION REPORTS SECOND QUARTER 2026 RESULTS

ENROLLMENT PROGRESSING IN ASCEND PHASE 1/2 GLOBAL CLINICAL TRIAL EVALUATING CR-001, A PD-1 X VEGF BISPECIFIC ANTIBODY, IN MULTIPLE SOLID TUMOR TYPES IN FIRST-LINE AND PREVIOUSLY TREATED PATIENTS CR-001 + SACITUZUMAB TIRUMOTECAN (SAC-TMT) PHASE 2 TRIAL IN NSCLC, FIRST ADC COMBINATION STUDY IN KELUN-BIOTECH COLLABORATION, UNDERWAY IN CHINA PHASE 1/2 TRIAL OF CR-003, AN ITGB6-TARGETED ADC, ONGOING IN CHINA; PHASE 1/2 GLOBAL TRIAL OF CR-002, A PD-L1-TARGETED ADC, ON TRACK TO INITIATE IN SECOND HALF OF 2026 MULTIPLE KEY CLINICAL DATA READOUTS ACROSS THE PORTFOLIO ANTICIPATED BEGINNING IN Q1 2027 COMPLETED $143.7 MILLION PUBLIC OFFERING EXTENDING EXPECTED CASH RUNWAY INTO THE SECOND HALF OF 2028 WALTHAM, MASS., JULY 30, 2026 (GLOBE NEWSWIRE) -- CRESCENT BIOPHARMA, INC. (CRESCENT OR THE COMPANY) (NASDAQ: CBIO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO RAPIDLY ADVANCING THE NEXT WAVE OF THERAPIES FOR CANCER PATIENTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026 AND RECENT BUSINESS HIGHLIGHTS.

CRESCENT BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

VIRTUAL INVESTOR "WHAT THIS MEANS" SEGMENT HIGHLIGHTS STRATEGIC WHITEHAWK COLLABORATION, ACCELERATING INDUSTRY VALIDATION OF NOVEL ADC PAYLOADS, AND AKARI'S DIFFERENTIATED PH1 PLATFORM

AKARI THERAPEUTICS CEO EXPLAINS WHY GROWING INDUSTRY DEMAND FOR NEXT-GENERATION ADC PAYLOADS POSITIONS THE COMPANY AT THE CENTER OF A MAJOR ONCOLOGY OPPORTUNITY

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.267 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.204 PER COMMON SHARE, REPRESENTING A 4.3% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE FROM THE THIRD QUARTER OF 2025. THE DIVIDEND IS PAYABLE AUGUST 14, 2026 TO STOCKHOLDERS O.

AGREE REALTY DECLARES MONTHLY COMMON AND PREFERRED DIVIDENDS

BEIJING, JULY 05, 2026 (GLOBE NEWSWIRE) -- INNOCARE PHARMA (HKEX: 09969; SSE: 688428), A LEADING BIOPHARMACEUTICAL COMPANY FOCUSING ON THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES, ANNOUNCED TODAY THAT THE FIRST PATIENT HAS BEEN DOSED IN THE CLINICAL TRIAL OF NOVEL CDH17 TARGETED ADC, ICP-B208, IN CHINA. DEVELOPED FROM INNOCARE'S IN-HOUSE ADC PLATFORM, ICP-B208 IS A NOVEL ADC COMPRISING A HUMANIZED ANTI-CDH17 MONOCLONAL ANTIBODY CONJUGATED TO A POTENT, IN-HOUSE INVENTED PAYLOAD VIA A PROTEASE-CLEAVABLE LINKER.

INNOCARE ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL OFNOVEL CDH17 TARGETED ADC ICP-B208 IN CHINA

LAUSANNE, SWITZERLAND, JULY 1, 2026 /PRNEWSWIRE/ --ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THAT THE COMPANY HAS MADE A GRANT OF OPTIONS TO PURCHASE AN AGGREGATE OF 17,000 OF THE COMPANY'S COMMON SHARES TO A NEW EMPLOYEE ON JULY 1, 2026 ("GRANT"). THE GRANT WAS OFFERED AS MATERIAL INDUCEMENT TO THE EMPLOYEE'S EMPLOYMENT.

ADC THERAPEUTICS ANNOUNCES NEW EMPLOYEE INDUCEMENT GRANT

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT IT WILL RELEASE ITS SECOND QUARTER 2026 OPERATING RESULTS AFTER THE MARKET CLOSES ON THURSDAY, JULY 30, 2026. A CONFERENCE CALL TO DISCUSS THE COMPANY'S OPERATING RESULTS IS SCHEDULED FOR FRIDAY, JULY 31, 2026, AT 10:00 AM ET. INTERESTED PARTIES AND SHAREHOLDERS MAY ACCESS THE CALL VIA TELECONFERENCE OR WEBCAST: TELECONFERENCE: USA TOLL FREE (833) 461-5787 INTERNATIONAL (626) 884-3620 .

AGREE REALTY ANNOUNCES SECOND QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

100 R/R DLBCL PATIENTS TREATED AT THE SELECTED 150 G/KG DOSE OF ZYNLONTA PLUS GLOFITAMAB FULL DATA EXPECTED IN FOURTH QUARTER OF 2026 LAUSANNE, SWITZERLAND, JUNE 30, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED THE COMPLETION OF ENROLLMENT IN THE LOTIS-7 PHASE 1B OPEN-LABEL CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) IN COMBINATION WITH THE BISPECIFIC ANTIBODY GLOFITAMAB (COLUMVI) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL). LOTIS-7 TRIAL ENROLLMENT IS NOW COMPLETE WITH 100 R/R DLBCL PATIENTS DOSED AT THE SELECTED 150 G/KG DOSE OF ZYNLONTA PLUS GLOFITAMAB.

ADC THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN LOTIS-7 PHASE 1B ZYNLONTA COMBINATION TRIAL

NEW YORK, JUNE 25, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA ("ADC" OR THE "COMPANY") (NYSE: ADCT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA - ADCT

PLANNED ~17% WORKFORCE REDUCTION EXPECTED TO GENERATE ANNUALIZED ESTIMATED SAVINGS OF APPROXIMATELY $10M, ENHANCING FINANCIAL FLEXIBILITY COMPANY FOCUSED ON DELIVERING UPCOMING REGULATORY AND CLINICAL MILESTONES, INCLUDING PLANNED LOTIS-5 SBLA SUBMISSION AND FULL LOTIS-7 DATA BY END OF 2026 LAUSANNE, SWITZERLAND, JUNE 24, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED A STRATEGIC REORGANIZATION TO FOCUS RESOURCES BEHIND KEY VALUE-DRIVING INITIATIVES IN SUPPORT OF THE ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) FRANCHISE. AS PART OF THE REORGANIZATION, ADC THERAPEUTICS PLANS TO REDUCE ITS WORKFORCE GLOBALLY BY APPROXIMATELY 17 PERCENT.

ADC THERAPEUTICS ANNOUNCES STRATEGIC REORGANIZATION TO SUPPORT ZYNLONTA GROWTH OPPORTUNITIES AND REGULATORY PRIORITIES

NEW YORK, JUNE 23, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA (ADC OR THE COMPANY) (NYSE: ADCT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

AU, SWITZERLAND & PRINCETON, N.J.--(BUSINESS WIRE)--ARARIS BIOTECH AG, A COMPANY ADVANCING A DIFFERENTIATED PIPELINE OF ANTIBODY-DRUG CONJUGATES (ADCS) THERAPIES, AND TAIHO ONCOLOGY, INC., A COMPANY DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR HEMATOLOGIC MALIGNANCIES AND SOLID TUMORS, BOTH MEMBERS OF THE TAIHO GROUP, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL TRIAL OF ARC-02, A CD79B-TARGETED ANTIBODY-DRUG CONJUGATE (ADC) FOR THE TREATMENT OF NON-HODGK.

ARARIS BIOTECH AG AND TAIHO ONCOLOGY ANNOUNCE DOSING OF FIRST PATIENT IN PHASE 1 TRIAL OF ARC-02, A NOVEL ADC FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA

PARIS--(BUSINESS WIRE)-- #ADC--ONE BIOSCIENCES RECEIVES PARIS-SACLAY CANCER CLUSTER (PSCC) BOOST GRANT TO DEVELOP FIRST SINGLE-CELL ASSAY FOR ANTIBODY-DRUG CONJUGATES THERAPIES.

ONE BIOSCIENCES RECEIVES BOOST FUNDING FROM PARIS-SACLAY CANCER CLUSTER TO ADVANCE THE FIRST SINGLE-CELL ASSAY APPROACH FOR ADC THERAPIES

NEW YORK, JUNE 18, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA ("ADC" OR THE "COMPANY") (NYSE: ADCT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

ZURICH, SWITZERLAND  JUNE 18, 2026 -- VERAXA BIOTECH AG (NASDAQ: VRXA; VERAXA), AN EMERGING LEADER IN DESIGNING NOVEL CANCER THERAPIES, TODAY ANNOUNCED THAT THE COMPANY HAS GENERATED NEW IN VITRO PROOF-OF-CONCEPT DATA VALIDATING ITS NOVEL BITAC-ADC TECHNOLOGY PLATFORM AND ITS POTENTIAL TO ENABLE MORE PRECISE AND TARGETED CANCER THERAPIES. VERAXA WILL ATTEND THE BIO INTERNATIONAL CONVENTION IN SAN DIEGO, CALIF.

VERAXA BIOTECH ESTABLISHES IN VITRO PROOF-OF-CONCEPT FOR NOVEL BITAC-ADC TECHNOLOGY PLATFORM AND LAUNCHES PARTNERING DISCUSSIONS AT BIO INTERNATIONAL CONVENTION 2026

COLLABORATION AIMS TO IDENTIFY BIOMARKERS PREDICTIVE OF ANTIBODY-DRUG CONJUGATE (ADC) TREATMENT RESPONSE USING 10X'S SINGLE CELL AND SPATIAL PLATFORMS PLEASANTON, CALIF., JUNE 17, 2026 /PRNEWSWIRE/ -- 10XGENOMICS, INC. (NASDAQ: TXG), THE LIFE SCIENCE TECHNOLOGY LEADER FOCUSED ON ACCELERATING SCIENCE AND ADVANCING HUMAN HEALTH, TODAY ANNOUNCED A RESEARCH COLLABORATION WITH CLEVELAND CLINIC, A NONPROFIT MULTISPECIALTY ACADEMIC MEDICAL CENTER THAT INTEGRATES CLINICAL CARE WITH RESEARCH AND EDUCATION, TO ADVANCE RESEARCH IN NOVEL DIAGNOSTICS FOR BLADDER CANCER.

10X GENOMICS AND CLEVELAND CLINIC COLLABORATE TO ADVANCE RESEARCH IN DIAGNOSTIC APPLICATIONS OF SINGLE CELL AND SPATIAL TECHNOLOGIES IN PATIENTS WITH BLADDER CANCER

NEW YORK, JUNE 16, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA (ADC OR THE COMPANY) (NYSE: ADCT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA  ADCT

HONG KONG, JUNE 15, 2026 /PRNEWSWIRE/ -- AKESO, INC. (HKEX: 9926) TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN ENROLLED IN THE PHASE IB/II CLINICAL STUDY (AK138D1-202) EVALUATING ITS INTERNALLY DEVELOPED NEXT-GENERATION HER3 ANTIBODY-DRUG CONJUGATE (ADC), AK138D1, AS EITHER MONOTHERAPY OR IN COMBINATION WITH IVONESCIMAB FOR THE TREATMENT OF ADVANCED BREAST CANCER. HER3 IS BROADLY EXPRESSED ACROSS VARIOUS SOLID TUMORS, INCLUDING BREAST, OVARIAN, COLON, GASTRIC, LUNG, SKIN, AND PANCREATIC CANCERS, AFFECTING MILLIONS OF PATIENTS GLOBALLY.

AKESO'S NEXT-GENERATION HER3 ADC AK138D1 COMBINED WITH IVONESCIMAB: FIRST PATIENT ENROLLED IN PHASE IB/II BREAST CANCER STUDY, ADVANCING THE IO2.0 + ADC2.0 STRATEGY

NEW YORK, JUNE 11, 2026 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA ("ADC" OR THE "COMPANY") (NYSE: ADCT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLEPEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JUNE 09, 2026 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ADC THERAPEUTICS SA (ADC OR THE COMPANY) (NYSE: ADCT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.267 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.204 PER COMMON SHARE, REPRESENTING A 4.3% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE FROM THE SECOND QUARTER OF 2025. THE DIVIDEND IS PAYABLE JULY 15, 2026 TO STOCKHOLDERS OF.

DISCUSSION HIGHLIGHTS GROWING IMPORTANCE ON NOVEL ADC PAYLOADS, AND AKARI'S ASCO DATA IN KRAS-DRIVEN CANCERS AND FUTURE POTENTIAL

AKARI THERAPEUTICS RELEASES CEO CORNER REFLECTING ON EVOLVING ADC LANDSCAPE AND AKARI'S DIFFERENTIATED PH1 PAYLOAD PLATFORM FOLLOWING ASCO 2026

COMPANY TO HOST CONFERENCE CALL TODAY AT 4:30 P.M. EDT LAUSANNE, SWITZERLAND, JUNE 3, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT) TODAY ANNOUNCED TOPLINE DATA FROM ITS PHASE 3 LOTIS-5 CONFIRMATORY TRIAL EVALUATING ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL).

ADC THERAPEUTICS ANNOUNCES RESULTS FROM LOTIS-5 PHASE 3 CONFIRMATORY CLINICAL TRIAL OF ZYNLONTA IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

Agree Realty

ADC

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC